Should I buy or sell BioRestorative Therapies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BRTX shares. View BRTX analyst ratings or view top-rated stocks .

What is BioRestorative Therapies' stock price target for 2024?

1 equities research analysts have issued 1-year price targets for BioRestorative Therapies' stock. Their BRTX share price targets range from $15.00 to $15.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 994.9% from the stock's current price. View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts .

How have BRTX shares performed in 2024?

BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTX stock has decreased by 21.3% and is now trading at $1.37. View the best growth stocks for 2024 here .

How were BioRestorative Therapies' earnings last quarter?

BioRestorative Therapies, Inc. (OTCMKTS:BRTX) released its quarterly earnings data on Friday, March, 29th. The company reported ($0.57) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies's stock reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX) , Sierra Oncology (SRRA) , Tonix Pharmaceuticals (TNXP) , iBio (IBIO) , Inovio Pharmaceuticals (INO) , Vaxart (VXRT) , Actinium Pharmaceuticals (ATNM) , OPKO Health (OPK) .

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:BRTX

BioRestorative Therapies (BRTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free BRTX Stock Alerts

$1.37

-0.07 (-4.86%)

(As of 05:21 PM ET)

Compare

Today's Range: $1.33
▼
$1.45
50-Day Range: $1.28
▼
$1.50
52-Week Range: $1.20
▼
$7.13

Volume: 162,028 shs
Average Volume: 552,871 shs
Market Capitalization: $9.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Stock Analysis Analyst Forecasts Chart Earnings Financials Headlines Insider Trades Ownership SEC Filings

Get BioRestorative Therapies alerts:

BioRestorative Therapies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 994.9% Upside
$15.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.25
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.52) to ($2.53) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.91 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
BioRestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioRestorative Therapies has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BRTX.

0.0

Dividend Strength

Dividend Yield
BioRestorative Therapies does not currently pay a dividend.
Dividend Growth
BioRestorative Therapies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BRTX.

2.4

News and Social Media Coverage

News Sentiment
BioRestorative Therapies has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for BioRestorative Therapies this week, compared to 0 articles on an average week.
Search Interest
3 people have searched for BRTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioRestorative Therapies insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.60% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BioRestorative Therapies are expected to grow in the coming year, from ($3.52) to ($2.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioRestorative Therapies is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioRestorative Therapies is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioRestorative Therapies has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About BioRestorative Therapies Stock (OTCMKTS:BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BRTX Stock News Headlines

April 19, 2024 | americanbankingnews.com

Reviewing BioRestorative Therapies (BRTX) & The Competition

April 19, 2024 | markets.businessinsider.com

Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 17, 2024 | msn.com

BioRestorative Therapies (BRTX) Price Target Decreased by 16.00% to 10.71

April 16, 2024 | americanbankingnews.com

Critical Survey: BioRestorative Therapies (BRTX) and The Competition

April 14, 2024 | finance.yahoo.com

10 Micro-Cap Healthcare Stocks Insiders Are Buying

April 13, 2024 | americanbankingnews.com

BioRestorative Therapies (BRTX) & Its Competitors Head to Head Contrast

April 13, 2024 | americanbankingnews.com

Head to Head Review: BioRestorative Therapies (BRTX) versus Its Rivals

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 16, 2024 | investing.com

BioRestorative Therapies Inc (BRTX)

February 14, 2024 | finanznachrichten.de

BioRestorative Therapies, Inc.: BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society 2024 Annual Meeting

February 6, 2024 | msn.com

PRSO, AKRO and MIRA among pre-market losers

December 20, 2023 | forbes.com

Gut Health Could Play A Role In How Blood Cancer Patients Respond To New Therapies

December 12, 2023 | marketwatch.com

BioRestorative Therapies Shares Rise 14% on Allowance for Patent Application

December 12, 2023 | finance.yahoo.com

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

November 9, 2023 | cnet.com

Best Light Therapy Lamps for 2023

October 9, 2023 | finance.yahoo.com

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

September 18, 2023 | seekingalpha.com

BioRestorative Therapies' 10% shareholder Broadrick Dale increases holding

September 18, 2023 | finance.yahoo.com

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

September 12, 2023 | finanznachrichten.de

BioRestorative Therapies, Inc: BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

September 12, 2023 | stockhouse.com

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

September 8, 2023 | finance.yahoo.com

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

August 30, 2023 | msn.com

$BRTX Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

August 29, 2023 | benzinga.com

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

August 15, 2023 | msn.com

Roth MKM Reiterates BioRestorative Therapies (BRTX) Buy Recommendation

August 8, 2023 | finance.yahoo.com

Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates

July 27, 2023 | msn.com

$BRTX: Insights From A Specialist On Stem Cell-Based Therapies And The Need For Spinal Care Reform

See More Headlines

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/29/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:BRTX
CUSIP: N/A
CIK: 1505497
Web: www.biorestorative.com
Phone: (631) 760-8100
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +941.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,500,000.00
Net Margins: -13,728.83%
Pretax Margin: -13,728.83%
Return on Equity: -120.47%
Return on Assets: -114.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.81
Quick Ratio: 14.81

Sales & Book Value

Annual Sales: $145,800.00
Price / Sales: 66.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.65 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 6,770,000
Free Float: 3,660,000
Market Cap: $9.75 million
Optionable: Not Optionable
Beta: 61.51

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Lance Alstodt (Age 53)
Chairman of the Board, President & CEO
Comp: $400k
Mr. Robert Eugene Kristal (Age 56)
Chief Financial Officer
Comp: $175k
Mr. Francisco J. Silva (Age 49)
Chief Scientist, VP of Research & Development, Secretary and Director
Comp: $375k
Mr. Robert Paccasassi (Age 55)
Vice President of Quality Assurance & Regulatory Compliance
Comp: $233.95k
Dr. Wayne J. Olan M.D.
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

BRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings or view top-rated stocks.
What is BioRestorative Therapies' stock price target for 2024?: 1 equities research analysts have issued 1-year price targets for BioRestorative Therapies' stock. Their BRTX share price targets range from $15.00 to $15.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 994.9% from the stock's current price.
View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts.
How have BRTX shares performed in 2024?: BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTX stock has decreased by 21.3% and is now trading at $1.37.
View the best growth stocks for 2024 here.
How were BioRestorative Therapies' earnings last quarter?: BioRestorative Therapies, Inc. (OTCMKTS:BRTX) released its quarterly earnings data on Friday, March, 29th. The company reported ($0.57) earnings per share (EPS) for the quarter. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%.

When did BioRestorative Therapies' stock split?: BioRestorative Therapies's stock reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.
What other stocks do shareholders of BioRestorative Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), OPKO Health (OPK).
How do I buy shares of BioRestorative Therapies?: Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BRTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioRestorative Therapies (BRTX) Stock Price, News & Analysis

BioRestorative Therapies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BioRestorative Therapies Stock (OTCMKTS:BRTX)

BRTX Stock Price History

BRTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

BRTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™